Study of Autonomic Nervous System Function in Adults with Episodic and Chronic Migraine and the Effects of CGRP Monoclonal Antibody Treatment

What this Trial Is About

Researchers are investigating how the autonomic nervous system functions in people with migraine and how it may change depending on whether they are between or during migraine attacks. The study also explores whether drugs called CGRP monoclonal antibodies, which block a messenger substance involved in migraine development, affect autonomic nervous system functions. Migraines are common and disabling, and while CGRP antibodies have been shown to reduce migraine frequency, their impact on autonomic functions is not well understood. The study involves patients with episodic or chronic migraine who have not responded to standard preventive medications, as well as healthy control participants without migraine or chronic disease. Patients will be observed over five months, including baseline visits and an evaluation visit, during which autonomic function scores will be measured and compared before and during treatment with anti-CGRP monoclonal antibodies such as Erenumab, Galcanezumab, or Fremanezumab. Controls will have one testing visit and a follow-up call. Participants will undergo standardized autonomic function tests measuring cardiovagal autonomic dysfunction and complete questionnaires assessing migraine impact, autonomic symptoms, quality of life, and psychiatric symptoms. These evaluations will occur at baseline, during migraine attack phases, and after five months of treatment or observation. Researchers will monitor changes in autonomic function scores and migraine-related questionnaires to understand the effects of migraine status and CGRP inhibition over time.

CGRP Inhibition, Autonomic Function, and Migraine